Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Best practice & research. Clinical gastroenterology - 1 Aug 2012

Asselah Tarik

Abstract excerpt

Approximately 170 million people are infected with hepatitis C virus (HCV) worldwide. Sustained virological response (SVR) is equivalent to viral eradication and associated with a reduction in the risk of cirrhosis and hepatocellular carcinoma. The treatment for genotype 1 HCV chronic infection is the addition of a protease inhibitor (telaprevir or boceprevir) to the pegylated-interferon (PEG-IFN) plus ribavirin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Liver Cirrhosis
Share to Oligopeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proline

Share to Protease Inhibitors

Share to Recurrence

Share to Retreatment

Share to Ribavirin

Source

Identifiers

PMID: 23199504
DOI: 10.1016/j.bpg.2012.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.PMID 23199504Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

The role of triple therapy in HCV genotype 1-experienced patients.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Semantic proximity Read ↗

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.